Clinical Trials Logo

Salivary Gland Cancer clinical trials

View clinical trials related to Salivary Gland Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05694819 Active, not recruiting - Clinical trials for Salivary Gland Cancer

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

Start date: April 17, 2020
Phase: Phase 2
Study type: Interventional

This study is an open-label phase 2 study to evaluate the safety and efficacy of Darolutamide monotherapy in patients with androgen receptor-positive salivary gland carcinoma. Moreover, this study will evaluate the safety and efficacy of Darolutamide and Goserelin combination in patients with androgen receptor-positive salivary gland carcinoma.

NCT ID: NCT05010629 Active, not recruiting - Metastatic Cancer Clinical Trials

9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma

Start date: September 14, 2021
Phase: Phase 2
Study type: Interventional

This trial is investigating an intravenous (IV) medication called 9-ING-41 in combination with chemotherapy (carboplatin) for the treatment of advanced salivary gland cancers. The names of the study drug(s) involved in this study are: - 9-ING-41 (a GSK-3β inhibitor) - Carboplatin chemotherapy

NCT ID: NCT05008237 Active, not recruiting - Clinical trials for Salivary Gland Cancer

Weekly Docetaxel Plus Cisplatin as First-line Chemotherapy in Metastatic Salivary Gland Cancer Patients : a Multicenter Phase II Study

Start date: May 2, 2014
Phase: Phase 2
Study type: Interventional

Cisplatin plus weekly docetaxel as first-line chemotherapy in metastatic salivary gland cancer patients : a multicenter phase II study

NCT ID: NCT04249947 Active, not recruiting - Prostate Cancer Clinical Trials

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Start date: February 28, 2020
Phase: Phase 1
Study type: Interventional

An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC and SGC.

NCT ID: NCT03781986 Active, not recruiting - Clinical trials for Salivary Gland Cancer

APG-115 in Salivary Gland Cancer Trial

Start date: October 28, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II trial to evaluate the efficacy of APG-115 +/- Carboplatin for the treatment p53 wild-type malignant salivary gland cancer. Part 1 consisted of 2 arms, arm A (APG-115 monotherapy) and arm B (APG-115 + Carboplatin) and was terminated early. Part 2 is a single arm study (APG-115 monotherapy).

NCT ID: NCT03172624 Active, not recruiting - Clinical trials for Salivary Gland Cancer

Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer

Start date: May 26, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out what effects, good and/or bad, treatment with two drugs called nivolumab and ipilimumab have on the participant and salivary cancer.

NCT ID: NCT02069730 Active, not recruiting - Clinical trials for Salivary Gland Cancer

A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes

Start date: June 2014
Phase: N/A
Study type: Interventional

This is a study of select drug therapies in patients with salivary gland cancer. The study has two phases: a molecular profiling phase (phase 1) and a treatment phase (phase 2). Based on the Molecular profiling results in phase the participants will receive matched treatment if a specific aberration is identified or will receive treatment with Selinexor if unmatched and no druggable aberration is identified.

NCT ID: NCT01969578 Active, not recruiting - Clinical trials for Salivary Gland Cancer

Androgen Deprivation Therapy in Advanced Salivary Gland Cancer

Start date: September 24, 2015
Phase: Phase 2
Study type: Interventional

Salivary Gland (SG) Cancers are a rare and heterogeneous group of tumors, usually approached by multidisciplinary teams in high specialized centers. Until today no standard of care exists to treat these cancers. The identification of a target, the androgen receptor, in SG tumors has allowed for new treatment strategies options for this rare group of diseases. As a matter of fact, strong positivity for androgen expression has been found in salivary duct carcinoma and adenocarcinomas. The purpose of this study is therefore to evaluate the efficacy and safety of chemotherapy versus androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic AR expressing SGCs. The study will include two cohorts of patients: Cohort A, which comprises chemo-naïve patients, and Cohort B, which comprises pretreated patients.